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Introduction
Gastrointestinal stromal tumors (GISTs) are rare can-
cers, accounting for 0.1–3.0% of all gastrointestinal
neoplasms [1]. These tumors are now defined as
mesenchymal tumors of the gastrointestinal tract,
featuring expression of the c-kit protein (CD-117) on
immunohistochemistry staining [2–6]. Most GISTs de-
tected were asymptomatic and discovered incidentally,
typically only at laparotomy performed for cancer survey
[7] or on radiologic investigation [5]. It is difficult to
diagnose GISTs preoperatively. Detailed history taking,
comprehensive physical examination, and extensive
imaging studies using ultrasound and computed
tomography may still provide results that, on most
occasions, prove to be deceptive with regards to tumor
identification. Here, we report two cases of GISTs aris-
ing from the ileum and jejunum, both of which appeared
to mimic gynecologic tumors. We also performed




Our gastrointestinal outpatient department referred
an 83-year-old postmenopausal Taiwanese woman,
gravida 7, para 7, to us after having detected a large low
abdominal mass. The patient had presented sympto-
matically with poor appetite, abdominal fullness and
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constipation for the preceding 3–4 days. There was no
apparent loss in body weight, change in urination habits,
or abnormal vaginal bleeding.
A physical examination revealed a low abdominal
pelvic mass of approximately 20 weeks’ gestational
size, arising from the suprapubic region and extending
to the umbilicus. A pelvic mass was found upon pelvic
examination. An abdominal ultrasound revealed an
atrophied uterus measuring 3.3 cm in length, and a
large mid-lower abdominal mass with heterogeneous
echogenicity and an irregular anechoic area within the
mass, somewhat suggestive of a huge cystic degenerated
myoma. We were not able to identify any connection
between the patient’s uterus and the mass since the
tumor was too large and the uterus too small to obtain
a clear view. A computed tomography (CT) scan revealed
that the lesion was a huge heterogeneous enhanced
mass with no real clear interface with the uterus,
suggesting a tumor of uterine origin, there being no
evidence of lymphadenopathy, hepatic, liver or
pancreatic disease. This patient had undergone prior
surgery for an inguinal hernia some 20 years previously
and had denied any history of medical disease. All
routine blood and biochemical markers were normal.
The levels of tumor markers assessed, including CA-
125 and carcinoembryonic antigen (CEA), prior to the
patient’s intended surgical procedure were within the
normal ranges.
An exploratory laparotomy under general anesthesia
was performed under the suspicion of a malignant
leiomyoma of the uterus. A huge intratumoral necrotic
thin-walled pelvic tumor measuring approximately 20 =
15 cm in diameter was encountered; the tumor adhered
densely to the ileum and the bladder dome. The uterus
and both adnexae appeared normal. There were multiple
nodules (between 0.5 and 1.5 cm in diameter) seeded
over the entire bowel. The parasurgical report by frozen
section noted the presence of a “myogenic tumor”. In
order to completely extirpate the tumor, the small
intestine was segmentally resected and repaired with an
end-to-end anastomosis. Partial cystectomy of the
bladder was conducted as well. Microscopic examination
revealed interlacing fascicles of bland-appearing spindle
cells with slightly increased cellularity, but rarely any
mitotic figures (two mitoses per 50 high-powered fields,
hpf). The tumor appeared to develop from the intestinal
wall and invade directly into the urinary bladder dome.
Immunohistochemical stains confirmed the tumor’s
reactivity against an antibody to c-kit. A diagnosis of a
low-grade GIST of the ileum was made following the
operation. The patient was discharged a week later in a
satisfactory condition, but was lost to follow-up 2
months later.
Case 2
A 48-year-old Taiwanese woman, gravida 1, para 1, was
admitted to our hospital in September 2003 complaining
of intermittent right lower abdominal pain and urinary
frequency over the preceding 4 months. This patient
had a history of abdominal total hysterectomy and
colpopexy due to uterine prolapse approximately 8
years previously. In addition, the patient had suffered
from hyperthyroidism and chronic hypertension over
the past almost 30 years, although her condition had
been stabilized with regular medication during the
intervening period. The patient revealed no history of
nausea, change in gastrointestinal habits, or abnormal
vaginal bleeding preceding her presentation at our
hospital.
A physical examination revealed a tense, firm, pelvic
mass of approximately 21-weeks’ gestational size. Upon
pelvic examination, a huge pelvic mass was identified;
an abdominal ultrasound revealed a large irregularly
shaped tumor featuring a well-circumscribed border
that extended beyond the umbilicus. The tumor was
multicystic in appearance with papillary growth apparent
in the solid parts of the tumor. Color Doppler study
disclosed hypovascularity within the tumor. A CT scan
revealed a huge complex tumor of varying density lying
between the lower abdomen and the pelvic cavity. The
tumor contained inhomogeneous cystic components
mixed with solid elements and was accompanied by
papillary growth soft-tissue foci. Lymph nodes were
detected at the left common iliac chain and ascites
appeared to be minimal. A small, ill-defined, low-density
nodule was apparent at hepatic segment 7, indicating
the possibility of tumor-associated liver metastasis. All
routine blood and biochemical markers were normal.
Levels of tumor markers were assessed prior to surgery,
including CA-125 (46.13 U/mL; normal range, 0–35 U/
mL), CA-199 (11.81 U/mL; normal range, 0–37 U/mL)
and CEA (1.18 ng/mL; normal range, 0–5 ng/mL).
An exploratory laparotomy under general anesthesia
was performed under the suspicion of a malignant
ovarian tumor. A huge fragile pelvic tumor measuring
about 20 = 20 cm in diameter, with 1,600 mL of bloody
content emerging from the antimesenteric side of the
jejunum at 40 cm below the Treiz ligament, was
encountered (Figure 1). The tumor densely adhered to
the jejunum but only loosely to the bladder dome. Both
ovaries appeared normal. Multiple nodules measuring
0.5–1.5 cm in diameter were noted, seeded over the
peritoneum, small bowel and pelvis. Parasurgical frozen-
section biopsy demonstrated the presence of spindle-
cell type tumors, favoring the diagnosis of a sarcoma,
although GIST could not be completely ruled out. The
jejunum was segmentally resected and repaired with an
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end-to-end anastomosis. Microscopic examination
revealed a proliferation of spindle cells that were ar-
ranged in a short whirl-like pattern or as focal inter-
lacing bundles within the muscular propria of the je-
junum. Prominent nuclear palisading, mild nuclear
pleomorphism and rare mitoses (up to three mitoses
per 50 hpf) were noted. The tumor revealed evidence of
focal hemorrhage and necrosis. Immunohistochemical
staining confirmed the tumor’s reactivity to c-kit anti-
body (Figure 2). A diagnosis of jejunal GIST with a
high risk of aggressive behavior was made. The patient
was discharged 1 week later in a satisfactory condition
and commenced taking imatinib (Glivec®, Novartis
Pharma AG, Basel, Switzerland) 1 month later. She is
continuing to receive follow-up investigation and
treatment at our general surgery department.
Discussion
GISTs are a group of tumors with malignant potential
that are currently believed to derive from mesenchymal
stem cells, the interstitial cells of Cajal (intestinal pace-
maker cells), or from more primitive stem cells from
which both Cajal cells and smooth muscle cells arise [2,
3,5,8]. Such tumors exhibit a broad spectrum of clinical
behavior from benign to malignant, and somewhere
between 10% and 30% of cases are malignant [1,7].
In general, it would appear that a GIST may arise from
any location in the gastrointestinal tract. It affects
mostly the stomach (60–70%), followed by the small
bowel (25–35%), colorectal areas (5%) and, extremely
rarely, the esophagus (< 2%) [2,4]. Some GISTs may
also appear to present in the omentum, mesenteries,
and retroperitoneum as primary tumors, but most of
these are metastases from the stomach or intestine [1,
3,4]. The majority of affected patients are middle-aged
or older, and there does not appear to be any sexual
preponderance [1,5]. Recent studies have revealed that
up to 94% of GISTs express a growth factor receptor
with tyrosine kinase activity, named c-kit [5].
Immunochemical staining for CD-117 (the c-kit proto-
oncogene product) and CD-34 (a sialylated trans-
membrane glycoprotein found in mesenchymal cells
and that appears to be reactive for 70–80% of GISTs)
are suggested to be sensitive markers for GISTs [2,3,
5,6]. CD-117 is currently believed to be the only diag-
nostic immunochemical staining technique required
for the unambiguous detection of GIST [1,8], and its
application in our patients confirmed that both had
GISTs.
The modes of presentation of GISTs can depend on
tumor size and location, but, in the majority of cases,
GIST remains silent in presentation [1]. Most small
GIST tumors are typically asymptomatic and are
discovered only incidentally at laparotomy performed
for other reasons or on radiologic examination [7]. For
larger GIST tumors, the patient may present with vague
abdominal discomfort, fullness, pain, the presence of a
palpable mass, and gastrointestinal hemorrhage if
the tumor has caused mucosal ulceration or signs of
obstruction [2,7]. Many patients, however, may need
more time to recognize the relative significance of such
symptoms. Melena or an acute abdominal condition
associated with mucosal ulceration, intestinal
obstruction, invagination, or tumor rupture with hemo-
peritoneum, are present in a large proportion of GIST
patients (30–50%). Surgical emergency is always
inevitable, and it appears to be the only means by which
the true nature of the tumor may be determined,
particularly in combination with histologic confirma-
tion [1–3,5,7].
Figure 1. A huge fragile pelvic tumor measuring approximately
20 = 20 cm in diameter, featuring 1,600 mL of bloody content,
and emerging from the antimesenteric side of the jejunum at a
position 40 cm below the Treiz ligament.
Figure 2. Immunohistochemical staining of CD-117 shows
diffuse cytoplasmic staining of almost all tumor cells.
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Case 1 presented with non-specific gastrointestinal
discomfort, which can easily be explained as a con-
sequence of the mass compression effect of a huge
uterine myoma. Her tumor markers were normal, and
the results of imaging studies had convinced us to make
a presumption of huge leiomyoma uterine, which is the
most commonly seen intra-abdominal large tumor in
females. Case 2 showed a similar picture: an apparent
mass compression effect, tolerable abdominal pain,
slight elevation of the tumor marker CA-125, and a
failure to identify the involved ovary (both from a pelvic
examination and by imaging studies); all ultimately led
us to a misdiagnosis at the time of patient examination.
There are only a few large intraperitoneal tumors
that typically arise amongst women. The differential
diagnoses for such lesions commonly include myomas
of a uterine origin, an ovarian origin, or originating in
the bowel, and also lymphomas and sarcomas. However,
in both our patients, presentation was associated with
only vague signs and symptoms of GIST, thus raising
the difficulty as regards to initial accurate disease
differentiation. Typically, GISTs involve the outer mus-
cular layer of the gastrointestinal tract and, mostly,
reflect exophytic growth [5]. When affected individuals
maintain an intact intestinal mucosa, as was the case
for our two patients, there is typically no ulceration,
bleeding or obstruction that would encourage the
clinician to include an intestinal tumor within the
differential diagnosis repertoire. Generally speaking,
most clinicians facing such a dilemma would seek
diagnostic assistance from imaging studies such as
sonography, CT and magnetic resonance imaging in
order to attempt to determine the origin of the tumor,
to depict the full extent of the (often large) tumor, as
well as to identify any possible distant metastases.
There still appears to be a general paucity of characteris-
tic radiologic criteria that may be used to effectively
distinguish GISTs from other large tumors preoperative-
ly [9].
It has been previously reported that a large proportion
of GIST patients (11–47%) have metastases upon first
diagnosis of their condition [1]. The liver and peritoneal
surfaces are the most commonly noted metastatic sites,
whilst the involvement of lymph nodes and extra-
abdominal sites is rare [1]. Complete surgical resection
of the tumor is the current standard treatment for GIST,
and STI571 (imatinib mesylate, Gleevec), a kit-selective
tyrosine kinase inhibitor, is the most effective adjuvant
therapy both pre- and post-surgery, even for an un-
resectable tumor [1,2,10,11].
There is no general agreement on the prognosis for
GIST [1], although the two most important histologic
criteria that differentiate malignant GIST tumors from
their benign counterparts are tumors featuring mitotic
figures more than 5/50 hpf and a size greater than 5 cm
in diameter [2]. Such GISTs are commonly associated
with a fairly high incidence of intra-abdominal recur-
rence, spread and liver metastasis [2]. In contrast to
this, tumors that are smaller than 2 cm and those with
mitotic figures less than 5/50 hpf have been shown to be
associated with a good prognosis [2,12].
In conclusion, GIST is an extremely rare tumor that
may present as a pelvic mass in women. At the time of
patient presentation, and then at diagnosis, every effort
should be made to successfully diagnose the condition.
These efforts should include a complete history, a review
of the patient’s general condition, a scrupulously detailed
physical examination, and a meticulous review of the
imaging results, so that the chances of accurately
determining the condition and differentiating between
possible origins of the tumor can be increased [13].
Some studies have reported on the relative practicability
and utility of fine-needle biopsy for the early diagnosis
of GIST [1], although the possibility of tumor rupture,
bleeding and seeding must always constitute a great
concern. Therefore, unless we have already ruled out the
possibility of a malignancy of gynecologic origin or can
conclusively exclude the above-mentioned biopsy risks,
we would not perform such a biopsy prior to surgery
[11]. It remains challenging for most gynecologists to
undertake and complete a preoperative summation
of GIST. Therefore, it is a surgeon’s responsibility to
be aware of and to be receptive to the possibility of a
diagnosis of GIST, and to recognize the tumor for what
it is, either prior to or during initial surgery, in order to
deliver the best treatment possible [1].
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